Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.
Schnittger S, Bacher U, Eder C, Lohse P, Haferlach C, Kern W, Haferlach T. Schnittger S, et al. Among authors: eder c. Exp Hematol. 2011 Jan;39(1):87-94. doi: 10.1016/j.exphem.2010.09.009. Epub 2010 Oct 1. Exp Hematol. 2011. PMID: 20888888
Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A. Weissmann S, et al. Among authors: eder c. Leukemia. 2012 May;26(5):934-42. doi: 10.1038/leu.2011.326. Epub 2011 Nov 25. Leukemia. 2012. PMID: 22116554
The role of different genetic subtypes of CEBPA mutated AML.
Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S. Fasan A, et al. Among authors: eder c. Leukemia. 2014 Apr;28(4):794-803. doi: 10.1038/leu.2013.273. Epub 2013 Sep 23. Leukemia. 2014. PMID: 24056881
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F, Eder C, Kohlmann A, Grossmann V, Kowarsch A, Kern W, Haferlach C, Haferlach T. Schnittger S, et al. Among authors: eder c. Haematologica. 2012 Dec;97(12):1890-4. doi: 10.3324/haematol.2012.065375. Epub 2012 Jun 24. Haematologica. 2012. PMID: 22733026 Free PMC article.
A novel hierarchical prognostic model of AML solely based on molecular mutations.
Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F, Schmid C, Wendtner CM, Staib P, Serve H, Kreuzer KA, Kern W, Haferlach T, Haferlach C. Grossmann V, et al. Among authors: eder c. Blood. 2012 Oct 11;120(15):2963-72. doi: 10.1182/blood-2012-03-419622. Epub 2012 Aug 20. Blood. 2012. PMID: 22915647 Free article.
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S. Grossmann V, et al. Among authors: eder c. Br J Haematol. 2013 Jun;161(5):649-658. doi: 10.1111/bjh.12297. Epub 2013 Mar 25. Br J Haematol. 2013. PMID: 23521373 Free article.
196 results